Wireless Capsule Endoscopy in Pediatric Gastrointestinal Diseases

Daisuke Tokuhara
Dept of Pediatrics, Osaka City University Graduate School of Medicine, Japan

1. Introduction

Capsule endoscopy (CE), which was invented to visualize the entire small intestine in a noninvasive manner was first described in 2000 (Iddan, 2000), was approved for adult patients in 2001 by Food and Drug Administration (FDA). More than 600,000 PillCam SB capsules, which is the first model for CE in the world, have been used worldwide since 2001 (Nakamura, 2009). In pediatric patients, Seidman et al. has first described the diagnostic value of CE (Seidman, 2002), and in 2003, FDA approved CE for pediatric patients ages 10 years and older. Emerging number of CE studies in children indicate the great demand for this population (Tokuhara, 2010; de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo Sant'Anna, 2005; Thomson, 2010; Ge, 2007; Postgate, 2009; Pinho, 2008; Shamir, 2007; Stiffler, 2003; Argüelles-Arias, 2004; Cohen, 2008), but performed number is relatively small (approximately 600, at the time of 2010) compared to adult cases (> 600,000), therefore, informations about indications, obtained results and risk of complications are not fully understood in pediatric patients. In pediatric patients, as well as in adults, CE is a first-line of examination to evaluate the entire small intestine and provides evidence for the diagnosis to the suspected small bowel disease especially in obscure gastrointestinal bleeding (OGIB) and suspected inflammatory bowel disease (IBD), on the other hand, accumulated studies are extending the indication of CE to protein loss, growth failure, abdominal pain, suspected polyp or graft-versus-host disease (GVHD) and regular follow-up for the known small bowel diseases. In this review, we summarize and discuss the capsule endoscopy system, indication, limitation, and future perspective of CE in pediatric patients.

2. General features of CE

2.1 Capsule endoscopy system

Capsule endoscopy system in children is almost same as that of adults. It is available to use a pediatric accessory kit with a recorder belt and sensor array, which are more appropriately sized for children (Fritscher-Ravens, 2009), on the other hand, CE, a PillCam SB capsule itself is the same type used by adults. The PillCam SB system has three components: a capsule endoscopy body, an external receiving antenna (consisting of eight sensor arrays) with attached portable hard disc drive (data recorder), and a customized PC workstation (RAPID: reading and processing images and data) with dedicated software for review and interpretation of images (Cave, 2004). CE is 26-mm long, 11-mm wide, weighs 3.4 g, records
images at a rate of 2 frames per second (fps), and has a battery life of about 8 hours. Image features include a 140°C field of view, 1:8 magnification, 1- to 30-mm depth of view, and a minimum size of detection of about 0.1mm. There is no capability of biopsy. After the patients ingest capsule, they can resume normal activities immediately, and are permitted to consume clear liquids and food at 2 h and 4 h thereafter (Tokuhara, 2010).

2.2 Abnormalities assessed by CE

CE visualizes various mucosal abnormalities such as ulcer, erosion, stricture, vascular anomaly, and mucosal protuberance such as polyp and tumor in pediatric patients as well as in adults (Table 1, Fig.1). In addition, Abnormal intestinal contents such as bleeding and

<table>
<thead>
<tr>
<th>Findings</th>
<th>Diagnosed or suggested diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ulcer</td>
<td>Celiac disease</td>
</tr>
<tr>
<td>Vascular anormalies</td>
<td>Hemangioma</td>
</tr>
<tr>
<td>Redness</td>
<td></td>
</tr>
<tr>
<td>Polyp</td>
<td></td>
</tr>
<tr>
<td>Erosion</td>
<td>Lymphonodular hyperplasia</td>
</tr>
<tr>
<td>Stricture</td>
<td></td>
</tr>
<tr>
<td>Atrophy</td>
<td>GVHD</td>
</tr>
<tr>
<td>Bleeding</td>
<td></td>
</tr>
<tr>
<td>White villi</td>
<td>Parasitic worm</td>
</tr>
<tr>
<td>Intestinal contents (ex. parasitic worm)</td>
<td></td>
</tr>
<tr>
<td>Mass</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Findings and diagnosed or suggested diseases by CE

Fig. 1. CE findings. (a) Normal jejunum. (b) Longitudinal ulcer (black arrow). (c) Stricture with redness and ulcer (arrows). (d) Active bleeding. (e) White villi. (f) Stenosis with ulcer.
parasitic worm can be seen (Table 1). Those abnormalities are highly detectable in the entire small intestine, to some extent, CE provide supportive information for the presence of abnormalities in the esophagus, stomach and colon. Transit time of CE and analyzed pathway by the software will help to assess the localization of detected abnormality in the small intestine. In pediatric patients with suspected small intestinal disease, CE detect abnormal findings in 55% (286/523) of cases (Tokuhara, 2010; de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo Sant'Anna, 2005; Thomson, 2010; Ge, 2007; Argüelles-Arias, 2004; Pinho, 2008; Stiffler, 2003). Based on the detected abnormalities by CE in addition to the clinical and/or other laboratory informations, various small intestinal diseases are diagnosed or suggested, or further elucidated of their involvements of small intestinal lesions in known diseases (Table 1).

2.3 Comparison with other modalities
A previous study demonstrated that CE is superior to small-bowel radiography, computed tomography enterography (CTE), and colonoscopy with ileoscopy in the evaluation of adult patients with suspected CD (Dionisio, 2010). As well as adult patients, CE is more sensitive than radiological and standard endoscopic modalities in the detection of small bowel CD distribution, OGIB source, and presence of polyps in children (Thomson, 2007; Guilhon de Araujo Sant'Anna, 2005). In addition, because of its non-invasive approach, even if initial study is non-diagnostic, repeat CE may increase diagnostic yield (Tokuhara, 2010). Further, even if initial CE study is technically inadequate (poor visualization and/or not reaching colon), it is possible to repeat examination compared to the invasive conventional examination. Almost at the same time with CE, double balloon enteroscopy (DBE), which is relatively a novel technique compared to the conventional examination, was developed to investigate the entire small intestine (Yamamoto, 2001). DBE can evaluate the small intestine as well as CE, but can gather biopsy specimens, and can carry out therapeutic procedures which are impossible by CE. In order to evaluate the entire small intestine, it is necessary to perform DBE 2 times with anterograde and retrograde routes. On the other hand, DBE often cannot visualize the entire small intestine. In regard to the application of DBE in children, previous studies reported the feasibility and usefulness of DBE in pediatric patients (Nishimura, 2010; Thomson, 2010; Leung, 2007). Another study described the successful use of DBE in 3 years old children with OGIB (Kramer, 2009). In regard to the differences in diagnostic accuracy and other advantages between CE and DBE, most of studies have concluded that CE was superior to the initial diagnosis but DBE was superior to treatment or histopathological diagnosis in adult patients with OGIB (Hadithi, 2006; Nakamura, 2006). In addition, lack of experience and expertise for smaller children are to be solved for the future extensive use of DBE in children (Leung, 2007). Thus it is expected that DBE is used in pediatric patient, but it is prefer that DBE is performed based on the screening by CE.

2.4 Preparations for CE
Generally, overnight fasting is used as a standard preparation for CE in pediatric patients (Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Atay, 2009). Diagnostic yield of capsule endoscopy depends on the quality of visualization of the small bowel wall and complete passage through the small bowel. Some abnormalities such as angiodysplasias are sometimes hampered by residual intestinal contents. Thus, a bowel preparation is studied previously, and sodium phosphate (Niv, 2005) or polyethylene glycol (PEG) (Viazis, 2004; Dai, 2005) has been described to offer improved visualization of the small intestine in adults.
In pediatric patients, colonoscopic bowel preparation was reported to offer the most favorable preparation. On the other hand, evaluation of entire small intestine is sometimes not completed because of prolonged gastric emptying and limited battery life (< 8h). In pediatric patients, completion rate of CE in the entire small intestine varies from 69 – 89 % (Tokuhara, 2010; Guilhon de Araujo Sant’Anna, 2005; Atay, 2009; de’Angelis, 2007; Ge, 2007; Moy, 2009; Postgate, 2009). In order to improve the completion rate, mosapride citrate or laxatives are one of candidate to increase the ability to observe the entire small intestine, but there is no systematic study in regard to the use of mosapride or laxatives as a preparation drug for CE study in pediatric patients. In adults, a previous study (Wei, 2007) reported oral 10mg mosapride citrate 1h before CE examination could accelerate the gastric emptying (13.5 min vs 34 min) and completion rate of small bowel examination ( 93.3 % vs 66.7 % ). In regard to the laxatives, a previous study (Franke, 2008) reported that a combination of bisacodyl and sodium phosphate significantly accelerated small bowel transit time (262 min ±55min vs 287 min ± 97min) but had no effect on the visibility of CE. Taken together, in order to increase the completion rate of small intestine and carefully examine the mucosal abnormality such as angiodysplasias, mosapride or laxatives might be effective preparation drug for CE in addition to the overnight fasting as the standard method.

3. Ages and indications for CE

3.1 Age
Accumulated studies confirmed that CE is safe and useful to children over 10 years of age (Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Argüelles-Arias, 2004), and application to this age group is considered as appropriate as well as adult. On the other hand, it is still controversial to use CE for the children under 10 years of age. Several studies described that CE has high diagnostic yield to those patients under 10 years of age (de’Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Ge, 2007), and their small body size don’t relate to the risk of capsule retention, which is the most serious complication in this modality as described in the latter paragraph. In addition, there was no difference in the gastric and small intestinal passage time between adult and pediatric patients (Ge, 2007). In young children (1.5-8 yr), a previous study reported CE detected small intestinal pathology in 45% (37 of 83 patients) in whom their indications are gastrointestinal bleeding, suspected Crohn's disease, abnormal pain, protein loss and malabsorption (Fritscher-Ravens, 2009). Because of no incidence of retention among those aged patients (1.5-7.9yr), CE is considered as feasible and safe down to the age of 1.5 yr. As another important aspect, swallowing of CE is unavoidable problem in small children. Based on the previous studies, most of pediatric patients (>10yr) can ingest CE (Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005). In regard to children > 4yr, 32% of children could ingest CE (Fritscher-Ravens, 2009). In case those young children cannot ingest capsule, endoscopic placement of the capsule into the duodenum is used (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). In the endoscopic placement, CE is released at the third part of the duodenum in order to prevent migration of CE back to the stomach (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). Some of devices are developed and reported (Orendain, 2010), on the other hand, mucosal injury by passage of device should be taken into consideration as a complication (Barth, 2004; Fritscher-Ravens, 2009). As another potential risk regarding the age, complication associated with deep intravenous sedation and general anesthesia for the endoscopic placement should be taken into consideration.
3.2 Indications
The indications for CE in pediatric patients are similar to that of adult patients; OGIB and suspected IBD are the major indications and suspected or known polyps such as Peutz-Jeghers syndrome are the following well-studied indication (Table 2). Known CD is also well-studied indication, but needs attention before the use of CE because of a relative high risk of capsule retention as described later. Malabsorption, protein loss, recurrent abdominal pain, and growth failure are the other minor indications, but sometimes important rather than adult population because of importance of mental and physical growth in children. Celiac disease is one of major indication in adult of Western countries such as USA and Europe, but it is rarely included as indication in children. On the other hand, because of non-invasive method, CE can be used repeatedly thus has been applied to get information to evaluate the treatment of known small bowel disease. Further, CE can provide supportive information about further examination, for example, when a physician determine the route of double balloon enteroscopy (via anal or oral) to resect polyps or take biopsies.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8~21</td>
<td>1.5~7.9</td>
<td>1.5~18</td>
<td>ND</td>
<td>10~18</td>
<td>9.4~15.9</td>
<td>3~18</td>
<td>10~18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>509</td>
<td>207</td>
<td>83</td>
<td>87</td>
<td>46</td>
<td>30</td>
<td>28</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBD</td>
<td>285 (56)</td>
<td>172 (83)</td>
<td>20 (24)</td>
<td>32 (37)</td>
<td>19 (41)</td>
<td>20 (67)</td>
<td>16 (57)</td>
<td>0 (0)</td>
<td>6 (50)</td>
</tr>
<tr>
<td>(Suspected IBD)</td>
<td>138 (27)</td>
<td>73 (35)</td>
<td>20 (24)</td>
<td>10 (11)</td>
<td>0 (0)</td>
<td>20 (67)</td>
<td>10 (36)</td>
<td>0 (0)</td>
<td>5 (42)</td>
</tr>
<tr>
<td>(Known IBD)</td>
<td>147 (29)</td>
<td>99 (48)</td>
<td>0 (0)</td>
<td>22 (25)</td>
<td>19 (41)</td>
<td>0 (0)</td>
<td>6 (21)</td>
<td>0 (0)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>OGIB</td>
<td>94 (18)</td>
<td>15 (7)</td>
<td>30 (36)</td>
<td>21 (24)</td>
<td>7 (15)</td>
<td>4 (13)</td>
<td>6 (21)</td>
<td>9 (56)</td>
<td>2 (17)</td>
</tr>
<tr>
<td>Polyps</td>
<td>55 (11)</td>
<td>2 (1)</td>
<td>0 (0)</td>
<td>33 (38)</td>
<td>11 (24)</td>
<td>6 (20)</td>
<td>3 (11)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>22 (4)</td>
<td>0 (0)</td>
<td>12 (14)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>0 (0)</td>
<td>1 (4)</td>
<td>5 (19)</td>
<td>4 (33)</td>
</tr>
<tr>
<td>Protein loss</td>
<td>13 (3)</td>
<td>1 (1)</td>
<td>9 (11)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (7)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Malabsorption</td>
<td>13 (3)</td>
<td>0</td>
<td>12 (14)</td>
<td>1 (1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Growth failure</td>
<td>5 (1)</td>
<td></td>
<td>0</td>
<td>0</td>
<td>5 (10)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4 (1)</td>
<td>4 (2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2. Indications for CE in pediatric patients.

Indications were summarized based on the previous CE studies for pediatric patients, which included at least 10 CE examinations for suspected small intestinal diseases (Tokuhara, 2010; de’Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo Sant’Anna, 2005; Thomson, 2010; Ge, 2007). We excluded the studies with limited indications (ex. abdominal pain alone). ( ), percentage. ND, not described.

3.2.1 Chron’s disease or inflammatory bowel disease
CE provides supportive evidence to diagnose or exclude small bowel CD. Thus, CE can be used in order to evaluate suspected CD or IBD, small bowel involvement of known CD, or follow-up of known small bowel CD. In adults, OGIB is the major indication rather than suspected IBD, however in children, suspected CD or IBD became the major indication (Table 2). Although indication rate of suspected CD or IBD depends on the physicians’ protocol and criteria, in regard to the papers in which all of small intestinal disease are included as indication, indication rate for suspected IBD varies from 0%-67% and total indication rate is 27%(138/509). If known CD or IBD are included, indication rate increase up to 56% (285/509) (Table 2). On the other hand, a previous study showed the indication rate of suspected CD as 7.8% in adult patients (Rondonotti, 2010). Because a known CD increases a risk of capsule retention possibly caused by an intestinal stricture (Cheifetz, 2006; Moy, 2009; Atay, 2009), it is
recommended to avoid the use of CE for the evaluation of known CD in both adult and children. In regard to the diagnostic accuracy, the previous pediatric study elucidated that CE was a more effective diagnostic tool in established CD patients compared with small-bowel radiography, CTE, and push enteroscopy (Thomson, 2007). Further, CE provides evidence not only to diagnose a patient having CD but also to exclude CD and discriminate CD from indeterminate colitis. The rate of diagnosis of CD in patients with suspected CD depends on the study, which was 12.5–70.6% in adult (Cheifetz, 2006; De Bona, 2006; Fireman, 2003), and 50–55% in children (de’Angelis, 2007; Fritscher-Ravens, 2009; Guilhon de Araujo Sant’Anna, 2005), thus criteria of suspected CD will be an important issue of concern.

3.2.2 OGIB and chronic anemia

Obscure gastrointestinal bleeding (OGIB) including chronic anemia is one of the major indication of CE in children as well as in adults (Table 2). In adults, a previous study showed the indication rate of OGIB as 43.4% (Rondonotti, 2010). Another study identified those patients of having significant findings; small bowel CD, angiodysplasia, Meckel’s diverticulum, and rarely parasitic infection such as hookworm (Sriram, 2004). In regard to the previous studies in which all of small intestinal disease are included as indication, indication rate of OGIB in pediatric CE varies from 7.2%–56.2%, and a total indication rate is 18.4% (94/509) (Table 2). In regard to the outcome of CE for the evaluation of source of OGIB, CD, polyp or polyposis and angiodysplasia are the most frequently detected source of OGIB in children (Table 3). Hemangioma, ulcerative jejunitis and Meckel’s diverticulum are also sometimes found in pediatric patients with OGIB. In regard to the source of venous malformations, Turner syndrome, which caused by loss of part or all of an X chromosome, is important in the field of pediatrics. In Turner syndrome, an intestinal telangiectasia is described as an association with an estimated incidence of 7% (Eroglu, 2002) and cause obscure GI bleeding. A previous report described that CE well detected multiple angiectasias and 2 large telangiectasia in the small intestine of a Turner syndrome with OGIB (Nudell, 2006). CE can determine the size, the location, and the number of telangiectasias, therefore contribute to select medical, surgical, or endoscopic therapy.

<table>
<thead>
<tr>
<th>Findings</th>
<th>Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total abnormal findings</td>
<td>69.3</td>
</tr>
<tr>
<td>CD</td>
<td>9.3</td>
</tr>
<tr>
<td>Polyp or polyposis</td>
<td>9.3</td>
</tr>
<tr>
<td>Angiodysplasia</td>
<td>9.3</td>
</tr>
<tr>
<td>Hemangioma*</td>
<td>6.7</td>
</tr>
<tr>
<td>Ulcerative jejunitis</td>
<td>5.3</td>
</tr>
<tr>
<td>Meckel’s diverticulum</td>
<td>4</td>
</tr>
<tr>
<td>Non-specific bleeding lesions</td>
<td>4</td>
</tr>
<tr>
<td>Multiple venous malformations</td>
<td>2.6</td>
</tr>
<tr>
<td>Giant ileal lymphoid nodular hyperplasia</td>
<td>2.6</td>
</tr>
<tr>
<td>Hemorrhagic gastroduodenopathy</td>
<td>2.6</td>
</tr>
<tr>
<td>Asmotic ulcer, Cobble stone appearance, Reduplication of the intestine, NSAID-induced mucosal lesions, Erosive gastroenteropathy, Ileal bleeding ulcer, Multiple small intestinal varices, Ileal stenosis, TAM</td>
<td>1.3</td>
</tr>
</tbody>
</table>

* includes Blue rubber bleb syndrome

Table 3. Outcome of CE in 75 patients with OGIB.
As another option, CE provides helpful information in the diagnosis of OGIB in patients who was suffered from malignant diseases such as leukemia and received chemotherapy and cord-blood transplantation or bone marrow transplantation. Our recent study described that CE provided a real-time imaging without patient’s stress and played a significant role in the management of OGIB in the malignant disease (Tokuhara, 2010). Chronic malignant diseases, such as leukemia, sometimes require repeated evaluation of gastrointestinal bleeding, but repeated conventional endoscopy is stressful and invasive, especially for seriously ill patients. Thus, repeated CE evaluation was acceptable to these patients and did not cause undue physical or mental stress. CE increases patient compliance and can therefore provide real-time informations about changes in gastrointestinal mucosal lesions without invasive bowel preparation.

### 3.2.3 Polyp or tumor

Although polyps and tumors are commonly detected in adult patients, it is rare to detect malignant tumor in pediatric patients thus polyp is a main indication in children. Following the 2 major indications (suspected IBD and OGIB), polyp or polyposis are well-performed indication (Table 2). In regard to the papers in which all of small intestinal disease are included as indication, indication rate of polyps in pediatric CE was 11% (55/509) (0-38%) (Table 2). The purpose of CE for the patients with suspected polyposis is diagnosis, follow-up, selection of route of endoscopy to resect polyp, or determine the necessity of laparotomy. Polyp is sometimes found in a patient with OGIB as an indication (Ge, 2007).

As a known polyposis, Peutz-Jeghers syndrome (PJS), familial adenomatous polyposis (FAP), juvenile poly, and Bannayan-Riley-Ruvalcaba syndrome have been reported. CE provided high diagnostic yield (100%, 5/5) to those pediatric patients with suspected polyposis (deAngelis, 2007). Another study examined 6 pediatric patients with known polyposis (3 PJS, 2 multiple juvenile polyposis, and 1 familial polyposis) and demonstrated that CE had 100% concordance with previously performed imaging modalities, but CE had a higher sensitivity revealing 50% more polyps than observed with the traditional imaging studies (Guilhon de Araujo Sant’Anna, 2005). Among polyposis, hereditary polyposis syndromes including PJS and FAP are known to develop benign small bowel pathology and cancer, thus the follow-up for PJS and FAP is especially important.

In regard to PJS, which is a rare autosomal dominant disorder characterized by mucocutaneous pigmentation and the hamartous polyps throughout the gastrointestinal tract, diagnosis is made by genetic analysis of STK11 gene mutation or 2 of the 3 clinical criteria: family history of PJS, hamartomatous polyps, and mucocutaneous pigmentation (Giardillelo, 2006). Intestinal polyps sometimes cause bleeding, anemia, and intussusceptions. Further, the patients with PJS have risk of malignancy including intestinal, breast, lung cancer in which average age of development of malignancy is the fourth decade of life (van Lier, 2010). Their first episode of manifestation also tend to occur during the first decade of life. Previous study revealed that 68% of children had undergone a laparotomy for bowel obstruction by the age of 18 years and many of these proceeded to a second laparotomy within 5 years (Hinds, 2004). Further, PJS sometimes need endoscopic removal of polyps or surgical treatment for bowel obstruction. Based on the accumulated studies, it has been recommended that endoscopic evaluation of the upper and lower gastrointestinal tract and imaging of the small bowel should be performed from the age of 8 years of earlier if symptoms are present (Hinds, 2004; Hyer, 2000). Therefore it is important to detect malignancies in an early phase and to remove polyps that may be premalignant and may
cause complications. In this regard, it is necessary to understand the size and localization of polyps in PJS. CE can evaluate the entire small intestine and contribute to select whether polyps should be observed or removed by upper endoscopy, colonoscopy, or double balloon enteroscopy. In comparison to conventional technique, a previous study demonstrated that CE detected significantly higher numbers of small-bowel polyps (at least 1 cm in diameter) than barium follow-through in adult PJS patients (Brown, 2006). In pediatric patients with PJS, CE significantly detected small polyps (<10 mm), and was assessed as a feasible, safe, and sensitive tool for small bowel screening in patients with PJS (Postgate, 2009). Therefore, CE can be used as a first-line surveillance approach in PJS.

In regard to FAP, which is an autosomal dominant condition with a defect in the APC gene on chromosome 5q21, if the patient was left untreated, there is a nearly 100% progression to colorectal cancer by the age of 35–40 yr (Hyer, 2000). The diagnosis is confirmed by finding adenomas during flexible sigmoidoscopy, or more than four pigmented ocular fundus lesions based on indirect ophthalmoscopy carries a 100% positive predictive value. In FAP-affected families with a known gene mutation, direct DNA genotypic analysis can determine whether a family member has the condition. In children with FAP, hepatoblastoma is important as complication rather than intestinal polyps (Aretz, 2006). Typical FAP is characterized by the occurrence of hundreds to thousands of colorectal adenomas. Adenomas usually appear within the second decade, and become symptomatic during the third decade of life. In the patients with FAP, they have high risk to develop duodenal adenoma and cancer, thus the duodenum and particularly the periampullary region is recognized as a major cause of morbidity and mortality. A previous CE study in adult patients with FAP reported that 76% of the patients with FAP with duodenal adenomas had additional adenomas in the proximal jejunum in addition to polyps in the distal jejunum or ileum, in contrast, in FAP patients without duodenal polyps, jejunal or ileal polyps occurred rarely (12%) (Schulmann, 2005). Thus, CE may be useful in selected patients with FAP. In children, the feasibility and usefulness of CE is not remarkable in FAP compared to PJS. It is necessary to accumulate further studies for FAP in children to evaluate the feasibility and usefulness of CE.

### 3.2.4 Abdominal pain

Several CE studies evaluated pediatric patients with abdominal pain. Based on the previous studies in which all of small intestinal diseases are included as indication, indication rate of abdominal pain in pediatric CE was 4% (20/509), varies from 0.0% to 33.0% depends on the studies (Table 2). As for usefulness of CE, it is controversial that abdominal pain can be an appropriate indication for CE. In adult patients, a previous study described 20 patients with chronic abdominal pain who were negative for extensive diagnostic workup, but no patients had clinically significant CE findings (Bardan, 2003). On the other hand, another study for adult patients demonstrated that abdominal pain with additional symptoms such as weight loss (>10% of body weight), inflammation shown by laboratory tests, chronic anemia, and suspected OGIB was associated with high diagnostic yield (May, 2007). In addition, another study applied to 16 patients with chronic abdominal pain without criteria for other gastrointestinal disorders and detected abnormal findings in 3 patients but in which only 1 patient, with additional symptom of weight loss, had relevant findings to abdominal pain in which ileal erosions and inflammation with a stricture which undetected by radiology (Spada, 2006). Based on previous studies in adult population, CE doesn’t provide diagnostic value against
abdominal pain itself, and strict patient selection on the basis of additional symptoms of signs is the key to increasing the field to capsule endoscopy in patients with chronic abdominal pain. In regard to children, a previous study reported that CE detected small bowel involvement in 1/10 patients with functional abdominal pain and most of patients don’t have the related organic etiology (Shamir, 2007). Another pediatric study described that 6/12 patients with abdominal pain had abnormal findings in which 3 with small bowel CD, 2 lymph nodular hyperplasia, and 1 blue rubber bleb syndrome, however it is undescribed whether those patients had additional symptoms or signs (Fritscher-Ravens, 2009). CE evaluation for a patient with recurrent abdominal pain reported a self-resolving ileojejunal intussusceptions in the mid-small bowel (Thomson, 2007). Taken together, as well as adult patients, it is indicated that CE doesn’t provide diagnostic value against abdominal pain in children, but additional symptoms or signs may increase the demand of CE. On the other hand, in treating children with FAP, it is important to give the family the reassurance that no serious disease in present according to physical examination and laboratory examination. In this regard, CE provides supportive informations to exclude the significant small bowel involvement. In adults, celiac disease might be suggested by CE in patients with abdominal pain (Culliford, 2005), but there is no report in pediatric population.

3.2.5 Protein loss
Protein loss might be included as indication for CE. A previous study evaluated 9 patients as having protein loss as a main indication, and revealed, in spite of normal duodenal biopsies, 6/9 had abnormal findings in which 4 had lymphangiectasia and 2 had lymph nodular hyperplasia (Fritscher-Ravens, 2009). Protein loss originated from the gut is often found in children with protein-losing gastropathy such as Menetrier disease (Tokuhara, 2007). In case of protein loss as an indication, lymphangiectasia is one of the most suspected and obtained result by CE. Several reports (Alkhouri, 2009; Tokuhara, 2010; Thomson, 2007) described 4 cases of protein loss were identified of having intestinal lymphangiectasia in pediatric patients.

3.2.6 Others
Malabsorption and growth failure are not main indication for CE, but CE sometimes contribute to evaluate those patients. A previous study (MoyL, 2009) reported that CE identified 4/7 pediatric patients with unexplained growth failure and normal small bowel series as having small bowel CD. In their study, 5/7 patients had positive anti-*Saccharomyces cerevisiae* antibodies (ASCA), a diagnostic serological marker for CD. In addition, 3 patients had growth failure with abdominal pain, 2 patients had growth failure with diarrhea and aphthous ulcers, and 1 patient had a family history of CD. Thus, Growth failure with additional symptom might be included as an indication for CE.

As an optional application, CE can be applied to evaluate the management of gastrointestinal diseases such as Henoch-Schonlein purpura (HSP) (Preud’Homme DL, 2006) and GVHD (Silbermintz, 2006; Yakoub-Agha I, 2004). In HSP, gastrointestinal bleeding occurs in ~50% of children, and massive bleeding may occur (Katz, 1991). A previous report demonstrated that CE contributed to identify the extent of the small intestinal involvement of HSP and confirmed the efficacy of cyclophosphamide therapy in improving the gastrointestinal lesions (Preud’Homme DL, 2006). In regard to GVHD, a previous study reported that in an 8-yr old child following allogeneic hematopoietic cell transplantation
who developed large volume bloody diarrhea requiring multiple blood transfusions that was resistant to aggressive therapy for GVHD, CE provided significant information not provided by upper endoscopy and colonoscopy that allowed for successful treatment changes (Silbermintz, 2006). Another study (Yakoub-Agha I, 2004) in adults demonstrated that CE provided more significant findings than upper endoscopy in the diagnosis of intestinal GVHD. The diagnosis of intestinal GVHD is based upon histological findings in endoscopic mucosal biopsy specimens. Therefore, it is sometimes required to use colonoscopy and upper endoscopy in order to diagnose and evaluate the extent of GVHD, but these tools cannot provide the entire small bowel information. In this regard, CE can provide supportive information about small bowel involvement of GVHD and the unknown source of OGIB and the effect of treatment. While DBE might be superior approach to CE in certain cases, it is an inappropriate option for exhausted children undergoing chemotherapy. In this regard, CE evaluation is acceptable to these patients and does not cause undue physical or mental stress, thus repeated CE examination is available.

4. Complications and contraindications

4.1 Complications

The most significant complication in the CE examination is capsule retention (Fig. 2). Capsule retention is defined as having a capsule endoscope remain in the digestive tract for a minimum of 2 weeks (Cave, 2005). A preceding normal small-bowel series does not preclude subsequent CE retention. The reported capsule retention rate in a study of 900 adult patients was approximately 0.7% (Barkin, 2002). It should be noted that there are potential risks of retention in CD, especially known CD. A previous study in adults (Cheifetz, 2006) revealed that CD is an potential risk of having the retention which is caused by unsuspected strictures, and retention was occurred in 13% (5 of 38) of patients with known CD, whereas in 1.6% (1 of 64) with suspected CD. When we reviewed previous CE studies of pediatric patients, which included at least 10 CE examinations for each patient, and found that 13 capsules had been retained in a total of 345 CE examinations giving an average frequency of capsule retention of 3.7% (range, 0–20%) (Table 4).

Fig. 2. Capsule retention.

Small bowel series showing a capsule retention at ileal stenoses in a 10-year-old girl with OGIB. After 2 months of retention, stenoses were surgically resected and a capsule was
removed. The patient was finally diagnosed as having non-specific multiple ulcers of small intestine (Tokuhara, 2010).
As well as adult cases, in also pediatric patients, a previous study retrospectively demonstrated that the risk of retention was significantly high (37.5% ; 3/8) in known CD, whereas none of patients with other indications showed the retention (Atay, 2009). When capsule retention happened, a risk of endoscopic or surgical removal might arise, although some reports described successful excretion of capsule after the corticosteroid therapy against gastrointestinal disease such as eosinophillic gastroenteropathy (Guilhon de Araujo Sant'Anna, 2005). As another severe insults related to capsule retention, a previous study described that adult patient with Crohn’s disease had a perforation after capsule endoscopy (Parikh, 2009). To decrease the risk of capsule retention and the following perforation, care should be taken in obtaining a history of problems with delayed gastric emptying, small bowel obstruction secondary to previous surgical changes, pyloric stenosis, Crohn disease, or Meckel diverticulum.

<table>
<thead>
<tr>
<th>(Retention)</th>
<th>Age/sex</th>
<th>Indication</th>
<th>Duration*</th>
<th>Symptoms</th>
<th>Outcome</th>
<th>Diagnosis (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tokuhara, 2010</td>
<td>10y, F</td>
<td>OGIB</td>
<td>2 months</td>
<td>None</td>
<td>Surgical ileal resection (stricture) **</td>
<td></td>
</tr>
<tr>
<td>de’Angelis, 2007</td>
<td>F</td>
<td>CD</td>
<td>3 months</td>
<td>None</td>
<td>Spontaneous excretion</td>
<td>CD</td>
</tr>
<tr>
<td></td>
<td>7y, F</td>
<td>OGIB</td>
<td>2 months</td>
<td>None</td>
<td>Surgical removal</td>
<td>Blinding ending loop</td>
</tr>
<tr>
<td>Atay, 2009</td>
<td>22y, M</td>
<td>Known CD</td>
<td>2 y</td>
<td>Unknown</td>
<td>Passed after medication (ND)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13y, M</td>
<td>Known CD</td>
<td>3 weeks</td>
<td>Nausea, emesis</td>
<td>Passed after steroid use (ND)</td>
<td></td>
</tr>
<tr>
<td>Thomson, 2010</td>
<td>&lt;16y</td>
<td>CD</td>
<td>4 weeks</td>
<td>ND</td>
<td>Passed after steroid use</td>
<td>CD (ND)</td>
</tr>
<tr>
<td>(Transit abnormality)</td>
<td>Atay, 2009</td>
<td>16y, M</td>
<td>Known CD</td>
<td>5 days</td>
<td>Abdominal pain</td>
<td>Surgery (stricure)</td>
</tr>
<tr>
<td>Guilhon de Araujo Sant’Anna, 2005</td>
<td>ND</td>
<td>Suspected IBD</td>
<td>10 days</td>
<td>None</td>
<td>Passed after steroid use</td>
<td>Eosinophilic enteropathy (stricture)</td>
</tr>
<tr>
<td>Moy, 2009</td>
<td>5-15y</td>
<td>1 suspected CD 3 known CD</td>
<td>ND</td>
<td>Abdominal pain</td>
<td>Surgical removal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ND</td>
<td>Abdominal pain</td>
<td>Surgical removal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ND</td>
<td>Abdominal pain</td>
<td>Passed after steroid use</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ND</td>
<td>Abdominal pain</td>
<td>passed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohen, 2008</td>
<td>ND</td>
<td>Known CD</td>
<td>ND</td>
<td>Ileal pouch</td>
<td>Endoscopic removal</td>
<td></td>
</tr>
</tbody>
</table>

ND, not described; *Duration of retention or transit abnormalities. ** The patient was finally diagnosed as non-specific multiple ulcers of small intestine.

Table 4. Capsule retention or regional transit abnormalities with symptoms or abnormal findings.
A novel dissolvable patency capsule will soon be available as a potential screening tool for patients deemed to be a high risk for retention. A patency capsule, which similar in size to PillCam SB and dissolves spontaneously because it is composed of lactose, has been developed by Given Imaging to assess bowel patency and degree of stenosis (Nakamura, 2008). If passage of the patency capsule is blocked, the capsule dissolves in 40-100h. The safety and efficacy of the initial model has been questioned (Gay, 2005), but recently, a new patency capsule model with a biodegradable body has been developed. The new patency capsule is a reliable indicator of functional patency in suspected or even known cases of intestinal stricture, and it can be used prior to conventional CE to predict and minimize the risk of retention and impaction (Banerjee, 2007).

As another rare condition, a previous study reported that a patient having a nervous temperament showed the discomfort, headache, and low blood pressure 2 h after capsule ingestion (Tokuhara, 2010). Patient temperament might affect outcome, especially among children; thus when pediatric patients have a nervous temperament, patient preparation, and explanation of the possibility of adverse effects to their legal guardians might be necessary.

### 4.2 Contraindications

It is not recommended to use CE in patients with known or suspected gastrointestinal obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and profile, patients with cardiac pacemakers or other implanted electromedical devices. It is not generally recommended to use CE in patients with difficulty of swallowing, but based on the development of capsule replacement, it is considerable if the pediatric patient is considered to take a benefit by capsule endoscopy even by endoscopic replacement under general anesthesia. There is no detailed limitation to use CE in small children but it is not recommended to use CE under 1.5yr or 10kg of body weight.

### 5. Perspective

Development of capsule endoscopy provides another 2 types of capsule endoscopies (PillCam ESO and PillCam COLON) which is for the esophagus and the colon, respectively (Eliakim, 2004; Saurin, 2007). The PillCam ESO capsule differs from the small-bowel capsule in that it has a camera at both ends of the capsule and captures a total of 14 images per second (7 per second for each camera). The battery life of the PillCam ESO is approximately 20 minutes and is approved for esophageal imaging only. The FDA approved the Pillcam ESO in November 2004. PillCam ESO and PillCam COLON have been demonstrated of their feasibility and usefulness in adult patients with GERD and esophageal varices, and colonic neoplasia, respectively. Future application of PillCam ESO and PillCam COLON is expected also in pediatric patients. As another interest of issue, therapeutic interventions using a capsule endoscope, such as delivery of medication to specific disease sites, smaller size of CE, higher quality image, biopsy with remote control are expected in future CE.

### 6. Conclusion

Capsule endoscopy is a non-invasive and effective approach to investigate the entire small bowel intestine in the suspected small intestinal diseases of children compared to the conventional examination methods (Barium series, computed tomography, push
enteroscopy), and provide the evidence in the diagnosis and give the supportive informations to evaluate the effect of the treatment and the clinical course. On the other hand, a physician and a patient must be aware of that CE is a first-line of surveillance but not necessarily a perfect tool to diagnose or exclude a disease thus other examination such as double-balloon endoscopy might be needed for histological examination or resection of lesions. In addition, especially in known CE, there is a risk of capsule retention which might need endoscopic or surgical removal. In those patients who are unable to swallow the capsule, endoscopic replacement of capsule is available. Major diagnostic yield is expected in patients having indications of suspected IBD, OGIB, and suspected polyps. Abdominal pain, malabsorption, protein loss, and growth failure might be included as indication especially when they accompanied additional clinical or laboratory signs suggesting inflammation. Relatively small number of CE studies in children compared to adult, it needs further consideration to use CE in small children at least under 10 years of age as well as children over 10 years of age and adults, it is clear that clinical application of CE in pediatric population is extending and there is small children who had benefit by the use of CE. For the future, together with accumulation of clinical studies, further development of CE such as smaller size of CE which is appropriate to small children, increased quality of images, option of biopsy, remote control are expected.

7. References


www.intechopen.com


www.intechopen.com
Wireless Capsule Endoscopy in Pediatric Gastrointestinal Diseases


As result of progress, endoscopy has became more complex, using more sophisticated devices and has claimed a special form. In this moment, the gastroenterologist performing endoscopy has to be an expert in macroscopic view of the lesions in the gut, with good skills for using standard endoscopes, with good experience in ultrasound (for performing endoscopic ultrasound), with pathology experience for confocal examination. It is compulsory to get experience and to have patience and attention for the follow-up of thousands of images transmitted during capsule endoscopy or to have knowledge in physics necessary for autofluorescence imaging endoscopy. Therefore, the idea of an endoscopist has changed. Examinations mentioned need a special formation, a superior level of instruction, accessible to those who have already gained enough experience in basic diagnostic endoscopy. This is the reason for what these new issues of endoscopy are presented in this book of New techniques in Gastrointestinal Endoscopy.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: